塞斯特林2通过AMPK激活和ROS抑制抑制RANKL诱导的骨质细胞形成
Kabsun Kim1, Jung Ha Kim2, Inyoung Kim1
1Department of Pharmacology, Chonnam National University Medical School, Gwangju, 61469, Republic of Korea.
Free radical biology & medicine
|December 15, 2023
概括
塞斯特林2 (Sesn2) 抑制骨质细胞形成,这是骨质损失的一个关键过程. 抗生素阿齐思罗米 (Azm) 增强了Sesn2,通过减少骨质再吸收,为骨质疏松症提供了潜在的治疗方法.
科学领域:
- 细胞生物学 细胞生物学
- 生物化学 生化学
- 药理学 药理学是指药理学的学科.
背景情况:
- 斯特林是具有抗氧化功能的应激反应蛋白,对细胞氧化还原平衡至关重要.
- 骨质细胞对骨重塑至关重要,它们的失调有助于骨质疏松症等骨疾病.
研究的目的:
- 研究塞斯特林2 (Sesn2) 在调节骨质细胞分化和功能中的作用.
- 通过准Sesn2.2,探索阿齐思罗米 (Azm) 作为骨质疏松症治疗剂的潜力.
主要方法:
- 在骨质细胞前体细胞中,Sesn2的过度表达和下调.
- 评估骨质细胞分化标志物 (c-Fos,NFATc1,TRAP,cathepsin K) 的使用情况.
- 对AMPK激活,Nrf2核转位和活性氧物种 (ROS) 生产的分析.
- 在活体研究中,在骨损失的小鼠模型中使用阿齐思罗米.
主要成果:
- 过度表达Sesn2显著抑制了核因子KB联体 (RANKL) 诱导的骨质结晶发生的受体激活剂.
- 阿兹胺 (Azm) 治疗诱导了Sesn2表达,抑制了RANKL诱导的骨质细胞分化,并减少了ROS的产生.
- 通过降低骨质细胞活性,Azm的使用改善了小鼠的RANKL诱导的骨损失.
结论:
- 通过AMPK/NFATc1通路,阿兹胺诱导的Sestrin2作为RANKL诱导的骨质细胞分化的负调节剂.
- 向Sestrin2代表了治疗骨质疏松症的潜在药理策略.
相关概念视频
PI3K/mTOR/AKT Signaling Pathway
3.6K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.6K
Osteoclasts in Bone Remodeling
3.0K
Osteoclasts are cells responsible for bone resorption and remodeling. They originate from hematopoietic progenitor cells present in the bone marrow. Numerous progenitor cells fuse to form multinucleated cells, each with 10-20 nuclei. A single osteoclast has a diameter of 150 to 200 µM. These cells have ruffled borders that break down the underlying bone tissue and release minerals such as calcium into the blood in bone resorption. Osteoclasts cling to bones with their ruffled edges during...
3.0K
MAPK Signaling Cascades
5.6K
Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
5.6K
The JAK-STAT Signaling Pathway
8.9K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
8.9K
TGF - β Signaling Pathway
7.4K
The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...
7.4K
mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K


